Literature DB >> 18328785

Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality.

David A Thorley-Lawson1, Karen A Duca, Michael Shapiro.   

Abstract

The really interesting thing about herpesviruses is that they can establish lifelong persistant infections in immunocompetent hosts. At first glance, they would seem to have very different ways of doing this. Here we will use as a model our current understanding of how the human herpesvirus Epstein-Barr virus establishes and maintains such an infection. We apply information from a wide range of sources including laboratory experimentation, clinical observation, animal models and a new computer simulation. We propose that the detailed mechanisms for establishing infection are dependent on the virus and tissues involved, but the strategy is the same - to persist in a long-lived cell type where the virus is invisible to the immune system and nonpathogenic.

Entities:  

Mesh:

Year:  2008        PMID: 18328785     DOI: 10.1016/j.it.2008.01.006

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  26 in total

1.  A model of host response to a multi-stage pathogen.

Authors:  Edgar Delgado-Eckert; Michael Shapiro
Journal:  J Math Biol       Date:  2010-10-02       Impact factor: 2.259

2.  Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BZLF1 gene.

Authors:  Tawin Iempridee; Shreyasi Das; Iris Xu; Janet E Mertz
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

3.  Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Authors:  Kun-Yi Lai; Ya-Ching Chou; Jiun-Han Lin; Yi Liu; Kai-Min Lin; Shin-Lian Doong; Mei-Ru Chen; Te-Huei Yeh; Sue-Jane Lin; Ching-Hwa Tsai
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

Review 4.  Herpesviral infection and Toll-like receptor 2.

Authors:  Ming-sheng Cai; Mei-li Li; Chun-fu Zheng
Journal:  Protein Cell       Date:  2012-08-04       Impact factor: 14.870

Review 5.  T-cell therapy in the treatment of post-transplant lymphoproliferative disease.

Authors:  Catherine M Bollard; Cliona M Rooney; Helen E Heslop
Journal:  Nat Rev Clin Oncol       Date:  2012-07-17       Impact factor: 66.675

Review 6.  Immunotherapy against cancer-related viruses.

Authors:  Haruko Tashiro; Malcolm K Brenner
Journal:  Cell Res       Date:  2016-12-23       Impact factor: 25.617

7.  Characterization of Epstein Barr virus latency pattern in Argentine breast carcinoma.

Authors:  Mario A Lorenzetti; Elena De Matteo; Hugo Gass; Paula Martinez Vazquez; Julia Lara; Pedro Gonzalez; María Victoria Preciado; Paola A Chabay
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

8.  Epstein-Barr virus-induced epigenetic alterations following transient infection.

Authors:  Krista J Queen; Mingxia Shi; Fangfang Zhang; Urska Cvek; Rona S Scott
Journal:  Int J Cancer       Date:  2012-11-02       Impact factor: 7.396

Review 9.  Epstein-Barr virus: more than 50 years old and still providing surprises.

Authors:  Lawrence S Young; Lee Fah Yap; Paul G Murray
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

10.  Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells.

Authors:  Mairaj Ahmed Ansari; Vivek Vikram Singh; Sujoy Dutta; Mohanan Valiya Veettil; Dipanjan Dutta; Leela Chikoti; Jie Lu; David Everly; Bala Chandran
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.